Aztreonam
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Aztreonam |
| DrugBank ID | DB00355 |
| Brand Names (EU) | Aztreonam, Emblaveo |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 99.73% |
Approved Indication (EMA)
Emblaveo is indicated for the treatment of the following infections in adult patients (see sections 4.4 and 5.1):• Complicated intra-abdominal infection (cIAI)• Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) • Complicated urinary tract infection (cUTI), including pyelonephritisEmblaveo is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options (see sections 4.2, 4.4, and 5.1).C
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | polyclonal hyperviscosity syndrome | 99.73% | DL |
| 2 | hyperamylasemia | 99.73% | DL |
| 3 | urinary tract infection (disease) | 99.69% | DL |
| 4 | congenital analbuminemia | 99.69% | DL |
| 5 | Ureaplasma urethritis | 99.59% | DL |
| 6 | gonococcal urethritis | 99.59% | DL |
| 7 | blood group incompatibility | 99.59% | DL |
| 8 | premalignant hematological system disease | 99.54% | DL |
| 9 | epiglottitis | 99.53% | DL |
| 10 | monoclonal gammopathy | 99.50% | DL |
| 11 | xanthogranulomatous pyelonephritis | 99.49% | DL |
| 12 | uterine inflammatory disease | 99.47% | DL |
| 13 | hematological disease associated with an acquired peripheral neuropathy | 99.46% | DL |
| 14 | septicemic plague | 99.38% | DL |
| 15 | congenital hematological disorder | 99.32% | DL |
| 16 | Peptostreptococcus infectious disease | 99.28% | DL |
| 17 | staphylococcus aureus infection | 99.19% | DL |
| 18 | toxocariasis | 99.13% | DL |
| 19 | streptococcal pneumonia | 98.90% | DL |
| 20 | urogenital tuberculosis | 98.84% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.